PT-141
Also known as: Bremelanotide
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II. It is FDA-approved as Vyleesi (2019) for hypoactive sexual desire disorder in premenopausal women only.
Who's worth your money for PT-141
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 40 scored sellers
$28.69 · 10mg · 99.0% purity
Best value
Lowest $/mg among scored sellers
$145 · 100mg · 99.8% purity
Most tested
32 independent COAs on file
$34.99 · 10mg · 99.7% purity
Average price
$4.55/mg
Sellers
75
45-day trend
-28%
60 of 75 sellers have a current price· 5 stale hidden· 15 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 1h ago
$2.87/mg -37% vs avg$28.69
10mg
- 🇺🇸 Peptide Partners99
via Disclosed Labs · 1h ago
$3.20/mg -29.7% vs avg$320
100mg
- 🇺🇸 Moglabs98
via Disclosed Labs · 1h ago
$3.60/mg -20.9% vs avg$36.00
10mg
- 🇺🇸 Hydro Research Peptides97
via Disclosed Labs · 1h ago
$5.00/mg +9.9% vs avg$50.00
10mg
- 🇺🇸 BioLongevity Labs96
via Disclosed Labs · 1h ago
$9.59/mg +110.8% vs avg$47.97
5mg
- 🇺🇸 Sunrise Bioresearch95
via Disclosed Labs · 1h ago
$1.45/mg -68.2% vs avg$145
100mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · 1h ago
$2.40/mg -47.3% vs avg$24.00
10mg
- 🇺🇸 Ion Peptide95
✓ verified at source · 1h ago
$3.70/mg -18.7% vs avg$37.00
10mg
- 🇺🇸 Profound Aminos95
via Disclosed Labs · 1h ago
$5.50/mg +20.8% vs avg$55.00
10mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 1h ago
$8.80/mg +93.3% vs avg$87.99
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch PT-141
Get one email when the market actually moves — no newsletter, no noise.
About PT-141
CAS
189691-06-3
Molecular formula
C50H68N14O10
Typical dose range
0.5–2 mg subcutaneous, administered ~45 minutes before activity; FDA-approved dose is 1.75 mg SC (max one dose per 24h, ≤8 doses/month)
Half-life
~2.7 hours (range 1.9–4.0 hours)
COAs for PT-141
177 third-party tests across 43 vendors. Each card links to the full report.
For
PT-141
by Sunrise Bioresearch· batch PTSEP26-01
For
PT-141
by Sunrise Bioresearch· batch PTSEP26-01
For
PT-141
by NG Peptide· batch pt10-04
For
PT-141
by Moglabs· batch PT-X-003
For
PT-141
by CertaPeptides· batch CP-2608-PT110
For
PT-141
by Peptide Plugs· batch 282510L-DK
For
PT-141
by Peptuvia· batch PSPT10-1
For
PT-141
by Glacier Aminos· batch PT10GA-04
For
PT-141
by Verified Peptides· batch PT05261410K
For
PT-141
by Certified Peptides· batch pt1-001
For
PT-141
by VoriLabs· batch VoriLabs PT14-2607-A
For
PT-141
by jdbioworks· batch 2026-002
For
PT-141
by Artisan Aminos· batch AA-PT10-049
For
PT-141
by Synthesis Peptides· batch PT10826
For
PT-141
by VoriLabs· batch PT14-2606-A
For
PT-141
by OROS Research· batch OR-LPPT10-626-B4
For
PT-141
by Blank Peptides· batch B-3230947-P
For
PT-141
by Verified Peptides
For
PT-141
by Orbitrex Peptides· batch PT10726US
For
PT-141
by NG Peptide· batch pt10-1640
For
PT-141
by Peptide Partners· batch PT202605
For
PT-141
by Novaglo Research· batch 30060326PT
For
PT-141
by Modern Research Peptides· batch 698221F
For
PT-141
by Nova Peptides· batch NV-P-U5U2
16 citations indexed for PT-141
review · 2026
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov
Background Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships.
review · 2026
Phytochemical-based nanomedicine as a promising therapeutic strategy for erectile dysfunction
Erectile dysfunction (ED) is a common condition among aging men, often associated with metabolic disorders, diabetes mellitus, hypertension, oligozoospermia, cardiovascular disease, sedentary lifestyles, chronic infections, and inflammation.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
review · 2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.
review · 2025
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions
Introduction Erectile dysfunction (ED) pathophysiology involves complex interactions between vasculogenic, hormonal, and neurological mechanisms, with endothelial dysfunction and oxidative stress playing crucial roles.
rct · 2015
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.